Premium
Saphenous vein graft lesions: Are second‐generation drug‐eluting stents better?
Author(s) -
Kolte Dhaval,
Dawn Abbott J.
Publication year - 2016
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.26390
Subject(s) - medicine , saphenous vein graft , myocardial infarction , bare metal , surgery , drug , vein , cardiology , radiology , stent , artery , restenosis , psychiatry
Key Points Long‐term outcomes were similar in patients treated with first‐ or second‐generation drug‐eluting stents (DES) for saphenous vein graft (SVG) lesions. Patients presenting with acute myocardial infarction as a result of occluded SVG may derive some benefit from the use of second‐ versus first‐generation DES Randomized clinical trials are needed to determine whether newer DES types including those with bioabsorbable polymer or scaffolds offer a distinct advantage in the treatment of SVG lesions.